LifeVantage Corporation reported QQ1 2025 revenue of $47.214 million, down 8.1% year over year, with FX headwinds reducing revenue by roughly $0.2 million. Excluding currency impact, revenue declined about 7.7%. The company maintained a robust gross margin of 79.9%, with non-GAAP SG&A of $14.7 million and adjusted EBITDA of $4.4 million (9.4% of revenue), up from $4.0 million a year earlier. Net income of $1.826 million yielded EPS of $0.15 (GAAP), while diluted EPS stood at $0.14. LifeVantage ended QQ1 2025 with a strong cash position of $14.6 million and no debt, and affirmed a disciplined capital return program including ~$1.1 million (≈140k shares) of share repurchases and a quarterly dividend of $0.04 per share.
Management emphasized the strategic significance of the MindBody GLP-1 System, unveiled in October 2024, which demonstrated differential demand with sequentially strong enrollments and a backorder situation of approximately 7 weeks due to rapid sell-out of initial Inventoried stock. Management projected MindBody to meaningfully expand total addressable market in weight management, with initial clinical signals including a 140% average GLP-1 increase and impressive weight-loss outcomes in a 12-week study, bolstering confidence in a multi-year growth runway. The company guided to full-year FY2025 revenue of $200–$210 million and adjusted EBITDA of $18–$21 million, with earnings per share in the range of $0.70–$0.80, flagging a preference for top-end performance given the MindBody momentum. The near-term risk factors include international macro headwinds, regulatory/regulatory-time considerations for international launches, and supply-chain constraints tied to MindBody’s initial demand surge. Overall, LifeVantage presents a defensible margin profile, strong liquidity, and a high-visibility growth catalyst in MindBody complemented by ongoing product-portfolio optimization and an entrepreneur-friendly compensation-plan evolution.